<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738764</url>
  </required_header>
  <id_info>
    <org_study_id>PDL192-1801</org_study_id>
    <nct_id>NCT00738764</nct_id>
  </id_info>
  <brief_title>A Trial of PDL192 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with
      advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study objective is to determine the maximum tolerated dose of PDL192 in subjects
      with advanced solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>after four weeks of dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and frequency of dose-limiting toxicities; The frequency, severity, and relationship of adverse events and serious adverse events;Incidence of abnormal findings in physical examinations and clinical laboratory values</measure>
    <time_frame>during estimated average 4 month treatment period and 90 day follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of PDL192 including maximum serum drug concentration, area under the concentration-time curve from time zero to infinity, systemic clearance, volume of distribution, and elimination half-life</measure>
    <time_frame>during estimated average 4 month treatment period and 90 day follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of PDL192-specific antidrug antibodies</measure>
    <time_frame>during estimated average 4 month treatment period and 90 day follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (Complete Response + Partial Response) and Disease control rate (Complete Response + Partial Response + Stable Disease)</measure>
    <time_frame>during estimated average 4 month treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDL192 Dose Level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDL192 Dose Level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDL192 Dose Level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDL192 Dose Level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDL192 Dose Level 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDL192 Dose Level 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDL192</intervention_name>
    <description>Humanized anti-TWEAK receptor monoclonal IgG1 antibody</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Eligible subjects will be considered for inclusion in this study if they meet all of the
        following criteria:

          1. Male or female, 18 years of age or older.

          2. Subjects with documented advanced solid tumors.

          3. Subjects who have previously failed all standard therapies or subjects who have a
             tumor where no standard therapy exists.

          4. A negative serum pregnancy test (women of childbearing potential only) at screening.
             Male or female subjects of reproductive potential must be willing to use adequate
             contraception during the duration of the study and for a minimum of 3 months after the
             end of treatment.

          5. Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (in accordance
             with national and local subject privacy regulations).

        Exclusion Criteria

        Subjects will be ineligible for this study if they meet any one of the following criteria:

          1. Symptomatic and progressive central nervous system (CNS) metastases or leptomeningeal
             metastases

          2. Diagnosis of glioblastoma

          3. Eastern Cooperative Oncology Group (ECOG) performance status &gt;= 2

          4. Abnormal hematologic values defined as:

               -  Hemoglobin level &lt; 9 g/dL

               -  Absolute neutrophil count (ANC) &lt; 1500/mm3

               -  Platelet count &lt; 100,000/mm3

          5. Abnormal kidney, liver, or pancreatic function defined as:

               -  Serum creatinine &gt; 1.5 x upper limit of normal value (ULN)

               -  Aspartate transaminase or alanine transaminase levels of &gt; = 2.5 x ULN

               -  Bilirubin &gt; ULN

               -  Amylase &gt; 1.5 x ULN

               -  Lipase &gt; 1.5 x ULN

          6. Known chronic viral hepatitis

          7. History of cirrhotic liver disease

          8. History of pancreatitis (patients with history of gall stone pancreatitis who are
             status post-cholecystectomy will be eligible)

          9. Acute cholecystitis within 6 months prior to the first dose of study drug

         10. Treatment with any investigational drug, antineoplastic agent, or antibodies within 21
             days prior to the first dose of study drug (6 weeks for vaccines or nitrosureas)

         11. Proteinuria &gt;1 g/24 hours (only subjects with &gt; = 2+ with dipstick test will undergo
             24 hour urine collection)

         12. Ongoing &gt;= Grade 2 toxicities resulting from prior therapies

         13. Received continuous systemic steroids at doses greater than 10 mg/day of prednisone or
             its equivalent within 30 days prior to the first dose of study drug (intermittent
             dexamethasone given for prophylaxis or treatment of emesis is permitted)

         14. Received any immunosuppressive agent (except steroids) within 21 days prior to the
             first dose of study drug

         15. Known hypersensitivity to any component of the PDL192 formulation

         16. Uncontrolled medical problems such as diabetes mellitus, pancreatitis, coronary artery
             disease, hypertension, unstable angina, arrhythmias, pulmonary disease, or symptomatic
             heart failure

         17. Female subjects who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihail Obrocea, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Biotherapeutics Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 53365</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 53364</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>January 5, 2012</last_update_submitted>
  <last_update_submitted_qc>January 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>antibody</keyword>
  <keyword>Phase 1 Clinical Trial</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

